Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) – Options on biopharmaceutical company, Aegerion Pharmaceuticals, Inc., are more active than usual this morning after one strategist established a sizable bull call spread in the January 2013 expiry. Shares in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) are down 1.0% on Monday afternoon to stand at $21.88 as of 12:15 p.m. ET in New York trading. The options player responsible for most of the volume in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) calls today appears to be extending bullish sentiment on the stock, banking gains on a position established back in November and initiating a fresh position in the January expiry options. It looks like the trader originally purchased 1,250 calls at the Dec. $20 strike for a premium of $1.60 apiece back on November 15th, and today sold those contracts at a premium of $1.95 apiece for a net profit of around $0.35 per contract. Next, the strategist appears to have purchased a 1,250-lot Jan. 2013 $25/$35 call spread for a net premium outlay of $0.95 each. The bull call spread positions the trader to profit should shares in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) rally 19% over the current price of $21.88 to top the breakeven price of $25.95 by expiration, with maximum potential profits of $4.05 per contract available in the event Aegerion’s shares surge 37% to top $30.00 at January expiration.
Equity Options Analyst
The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
